Latest Breaking News On - Depei wu - Page 2 : comparemela.com

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines News provided by Share this article Share this article SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China, added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for the treatment of re

Kyongsang buktoSouth koreaNew zealandHong kongWenming chenAsia pacificDepei wuChao yang hospital of the capital medical universityKaryopharm therapeutics incAntengene corporationEuropean commissionDrug administrationChinese medical education association committee on hematologyAntengene corporation limitedConnective tissue oncology societyMinistry of food